Both short-term and long-term prospects appear positive for Johnson & Johnson, despite some first-quarter performance fluctuations across segments. The strong pharma segment offsets weaknesses in the MD&D segment, with promising new drug launches and solid global reach. The consumer segment demonstrates recovery, and the companyâ€™s broad portfolio offers balance. Meanwhile, operational efficacy is reflected in the robust cash flow and strong first-quarter start. Based on the successful first quarter and promising pipeline and product launches, the stock is likely to experience a positive boost in the short term.
[1]